

March 2014



HESI Board Member Recognized for Occupational and Environmental Toxicology

Contributions. Congratulations to Professor Alan Boobis (Imperial College London) of the HESI Board of Trustees who received the [Royal Society of Chemistry's Toxicology Award](#) for his work on the human metabolism of carcinogens and his extensive involvement in scientific committees for the government of the United Kingdom, the European Commission, and other international groups.



HESI Science at the 2014 Annual Meeting of the Society of Toxicology in Phoenix,

Arizona. Click [here](#) to see the comprehensive list of scientific posters, symposia, and workshops that feature HESI science. Also, don't forget to [register](#) for the HESI CITE Seminar (formerly known as the HESI SOT Lunchtime Seminar) to be held Monday, 24 March 2014, at noon. This year's speaker is Dr. Peter Kuhn (Scripps Research Institute), a dynamic scientist who brings together physics and oncology to create powerful applied translational science for detection of circulating tumor cells.

NEW PUBLICATIONS

Lebrec H, Molinier B, Boverhof D, Collinge M, Freebern W, Henson K, Mytych DT, Ochs HD, Wange R, Yang Y, Zhou L, Arrington J, Christin-Piché MS, and Shenton J. (2014) [The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation.](#) *Regul Toxicol Pharmacol.* 69(1): 7-21.

Pettit SD. (2014) [From silos to multilingual science.](#) *Sci Trans Med.* 6, 223.



HESI and FDA representatives engage in a February 2014 RISK21 panel discussion.

HESI Shares RISK21 Approach with the US FDA. At the invitation of the US Food and Drug Administration (FDA) Center for Food Safety and Applied Nutrition, the HESI Risk Assessment in the 21st Century (RISK21) Technical Committee conducted a half-day seminar on the RISK21 approach on 18 February 2014 at FDA in College Park, Maryland. Approximately 50 FDA scientists from various centers participated in person and over 50 participants connected remotely via webinar or telephone. The seminar, organized by Dr. Sabine Francke-Carroll (FDA), Dr. Suzanne Fitzpatrick (FDA), and Dr. Michelle Embry (HESI), included introductory risk assessment perspectives from FDA and presentations by RISK21 leaders on the RISK21 problem formulation-based, exposure-driven, tiered data acquisition approach. A panel discussion with RISK21 and FDA representatives focused on the potential utility and applications of the RISK21 approach within FDA. Discussions are underway between HESI and FDA for a follow-up RISK21 workshop in fall 2014 with broader participation across US regulatory agencies. For additional information, contact Ms. Nancy Doerrer (ndoerrer@hesiglobal.org).

UPCOMING WORKSHOPS



Registration Is Now Open — Workshop on the Assessment of Respiratory Sensitization.

The HESI Immunotoxicology Technical Committee is organizing this event in Alexandria, Virginia, on 28–29 May 2014. This workshop will discuss the current state of the science for identification and characterization of respiratory sensitizer hazards, identify the near- and long-term information to facilitate development of validated standard methods and frameworks, and consider regulatory and practical needs regarding hazard management. For more information, visit the workshop [website](#) or contact Dr. Connie Chen (cchen@hesiglobal.org).

Registration Is Now Open — Workshop on Genetic Toxicology at the Crossroads: From Qualitative Hazard Evaluation to Quantitative Risk Assessment.

The HESI Genetic Toxicology Technical Committee is organizing this satellite workshop of the European Environmental Mutagen Society 2014 Annual Meeting hosted by the UK Environmental Mutagen Society in Lancaster, United Kingdom, on 10–11 July 2014. It is becoming increasingly apparent that the genetic toxicology community should move away from qualitative hazard-based approaches to quantitative risk-based methodologies to facilitate data interpretation in the context of informing human risk. The workshop will bring together experts in the fields of genetic and general toxicology, risk assessment, and computational biology representing industry, academia, and government to address and make recommendations on a path forward on this topic, including the identification of any key data gaps in our knowledge that require further research. Although the focus of this workshop is on genetic toxicology studies, the key learnings from this effort will have a much broader impact across various toxicology disciplines. For more information, visit the workshop [website](#) or contact Dr. Jennifer Young Tanir (jtanir@hesiglobal.org).



ILSI Health and Environmental Sciences Institute
1156 Fifteenth Street, NW Suite 200
Washington, DC 20005-1743
202.659.3306 phone
202.659.3617 fax

Please visit us at our [website](#), on [YouTube](#) or follow us on [Twitter](#) to receive announcements on new publications, upcoming meetings and conference, and other news.



FROM THE EXECUTIVE DIRECTOR

2014 is a year of milestones for HESI. We celebrate the 25th anniversary of the organization, the largest number of partner organizations (both public and private) that HESI has engaged in its history, the most submissions of new topics to HESI's Emerging Issues Committee, and more. Registration is now open for our June 2014 Annual Meeting. [Register now](#) to make this our most highly attended Annual Meeting yet and help us set new milestones for 2015!

Spencer D. Rebert